MIRM – Mirum Pharmaceuticals Inc
MIRM — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
14.64
Margin Of Safety %
Put/Call OI Ratio
0.58
EPS Next Q Diff
0.51
EPS Last/This Y
-13.77
EPS This/Next Y
13.95
Price
100.58
Target Price
138.21
Analyst Recom
1.07
Performance Q
-2.22
Upside
-606.0%
Beta
0.48
Ticker: MIRM
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-07-13 | MIRM | 118.93 | 0.39 | 0.53 | 2186 |
| 2026-07-14 | MIRM | 120.86 | 0.40 | 0.25 | 2219 |
| 2026-07-15 | MIRM | 121.07 | 0.40 | 999.99 | 2243 |
| 2026-07-16 | MIRM | 116.56 | 0.40 | 0.87 | 2248 |
| 2026-07-17 | MIRM | 118.6 | 0.41 | 0.06 | 2312 |
| 2026-07-20 | MIRM | 116.73 | 0.47 | 999.99 | 1853 |
| 2026-07-21 | MIRM | 117.01 | 0.47 | 3.31 | 1855 |
| 2026-07-22 | MIRM | 114.38 | 0.47 | 3.07 | 1855 |
| 2026-07-23 | MIRM | 114.32 | 0.48 | 1.60 | 1883 |
| 2026-07-24 | MIRM | 113.11 | 0.49 | 14.75 | 1897 |
| 2026-07-27 | MIRM | 114.22 | 0.64 | 0.00 | 2105 |
| 2026-07-28 | MIRM | 112.17 | 0.62 | 0.00 | 2133 |
| 2026-07-29 | MIRM | 107.64 | 0.62 | 0.39 | 2148 |
| 2026-07-30 | MIRM | 112.62 | 0.64 | 0.24 | 2147 |
| 2026-07-31 | MIRM | 105.9 | 0.64 | 1.00 | 2160 |
| 2026-08-03 | MIRM | 104.51 | 0.65 | 6.80 | 2186 |
| 2026-08-04 | MIRM | 104.39 | 0.68 | 0.00 | 2223 |
| 2026-08-05 | MIRM | 105.74 | 0.67 | 0.29 | 2227 |
| 2026-08-06 | MIRM | 94.19 | 0.67 | 0.42 | 2234 |
| 2026-08-07 | MIRM | 100.66 | 0.58 | 0.46 | 3714 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-07-13 | MIRM | 119.00 | -100.0 | - | -14.24 |
| 2026-07-14 | MIRM | 120.86 | -100.0 | - | -14.24 |
| 2026-07-15 | MIRM | 120.91 | -100.0 | - | -14.24 |
| 2026-07-16 | MIRM | 117.41 | -100.0 | - | -14.24 |
| 2026-07-17 | MIRM | 118.68 | -100.0 | - | -14.24 |
| 2026-07-20 | MIRM | 116.59 | -100.0 | - | -14.24 |
| 2026-07-21 | MIRM | 117.12 | -100.0 | - | -14.24 |
| 2026-07-22 | MIRM | 114.42 | -100.0 | - | -14.24 |
| 2026-07-23 | MIRM | 114.12 | -100.0 | - | -14.24 |
| 2026-07-24 | MIRM | 113.16 | -100.0 | - | -14.24 |
| 2026-07-27 | MIRM | 114.28 | -100.0 | - | -14.24 |
| 2026-07-28 | MIRM | 112.18 | -100.0 | - | -14.24 |
| 2026-07-29 | MIRM | 107.71 | -100.0 | - | -14.24 |
| 2026-07-30 | MIRM | 112.54 | -100.0 | - | -14.24 |
| 2026-07-31 | MIRM | 105.93 | -100.0 | - | -14.24 |
| 2026-08-03 | MIRM | 104.50 | -100.0 | - | -14.24 |
| 2026-08-04 | MIRM | 104.50 | -100.0 | - | -14.24 |
| 2026-08-05 | MIRM | 105.72 | -100.0 | - | -14.24 |
| 2026-08-06 | MIRM | 94.10 | -100.0 | - | -14.24 |
| 2026-08-07 | MIRM | 100.58 | -100.0 | - | -14.24 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-07-13 | MIRM | -0.61 | 10.73 | 15.06 |
| 2026-07-14 | MIRM | -0.61 | 10.73 | 15.06 |
| 2026-07-15 | MIRM | -0.61 | 10.73 | 15.06 |
| 2026-07-16 | MIRM | -0.61 | 10.73 | 15.06 |
| 2026-07-17 | MIRM | -0.60 | 10.73 | 15.06 |
| 2026-07-20 | MIRM | -0.60 | 10.81 | 15.06 |
| 2026-07-21 | MIRM | -0.60 | 10.81 | 15.06 |
| 2026-07-22 | MIRM | -0.54 | 10.81 | 15.06 |
| 2026-07-23 | MIRM | -0.54 | 10.81 | 15.06 |
| 2026-07-24 | MIRM | -0.42 | 10.81 | 15.06 |
| 2026-07-27 | MIRM | -0.42 | 10.88 | 14.64 |
| 2026-07-28 | MIRM | -1.46 | 10.88 | 14.64 |
| 2026-07-29 | MIRM | -1.46 | 10.88 | 14.64 |
| 2026-07-30 | MIRM | -1.46 | 10.88 | 14.64 |
| 2026-07-31 | MIRM | -1.46 | 10.88 | 14.64 |
| 2026-08-03 | MIRM | -1.46 | 11.78 | 14.64 |
| 2026-08-04 | MIRM | -1.35 | 11.78 | 14.64 |
| 2026-08-05 | MIRM | -1.36 | 11.78 | 14.64 |
| 2026-08-06 | MIRM | -1.36 | 11.78 | 14.64 |
| 2026-08-07 | MIRM | -1.36 | 11.78 | 14.64 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.8
Avg. EPS Est. Current Quarter
-0.71
Avg. EPS Est. Next Quarter
-0.29
Insider Transactions
-1.36
Institutional Transactions
11.78
Beta
0.48
Average Sales Estimate Current Quarter
180
Average Sales Estimate Next Quarter
185
Fair Value
Quality Score
25
Growth Score
52
Sentiment Score
43
Actual DrawDown %
22.6
Max Drawdown 5-Year %
-40.3
Target Price
138.21
P/E
Forward P/E
PEG
P/S
10.57
P/B
P/Free Cash Flow
EPS
-14.55
Average EPS Est. Cur. Y
-14.24
EPS Next Y. (Est.)
-0.29
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-139.18
Relative Volume
0.85
Return on Equity vs Sector %
Return on Equity vs Industry %
EPS 1 7Days Diff
EPS 1 30Days Diff
-14.24
EBIT Estimation
◆
MIRM
Healthcare
$100.65
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
39.3
Range 1M
28.1%
Sup Dist
10.9%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
-3124.5%
EPS NY
95.1%
52W%
59.1%
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+37.3% upside
Upside
+37.3%
Quality
25
MIRM — P/E HistoricalBiotechnology
Mirum Pharmaceuticals, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 433
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases; Brelovitug, for the treatment of chronic HDV infection, which is in Phase 2 clinical trial; and MRM-3379, that is in Phase 2 clinical study for the treatment of FXS. The company has a collaboration agreement with the Shire International GmbH; License Agreement with Pfizer Inc.; Sanofi-Aventis Deutschland GmbH; Novartis Pharma AG; Lonza Ltd.; Enthorin Therapeutics, LLC and Dart Neuroscience LLC; Asset Purchase Agreement with Asklepion Pharmaceuticals, LLC; License and Manufacturing Agreement with LGM Pharma; and Asset Purchase Agreement with Travere Therapeutics, Inc. The company was incorporated in 2018 and is headquartered in Foster City, California.
MIRM
Latest News
—
Caricamento notizie per MIRM…
stock quote shares MIRM – Mirum Pharmaceuticals Inc Stock Price stock today
news today MIRM – Mirum Pharmaceuticals Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch MIRM – Mirum Pharmaceuticals Inc yahoo finance google finance
stock history MIRM – Mirum Pharmaceuticals Inc invest stock market
stock prices MIRM premarket after hours
ticker MIRM fair value insiders trading